Bristol-Myers Squibb came into this Q3 2026 report with a stock that had gone largely sideways over the past month and down over the past quarter. The latest print told a sharper story. Shares climbed 1.8% to US$62.48 after the release, even as quarterly basic earnings per share of about US$1.06 were well below Q2 levels while revenue held near US$13.1b.
For a company often described as a durable cash generator, the main focal point this time is profit pressure. Net income from ongoing operations fell from US$3.3b in Q2 to about US$2.2b, a squeeze that matters far more than the modest move in the share price.
Like the income line at Bristol-Myers Squibb but uneasy about profit compression between Q2 and Q3? Consider screening for companies showing stronger earnings resilience and cleaner cash generation with our list of solid balance sheet and fundamentals stocks (25 results).
Q3 2026 Bristol-Myers Squibb Earnings Summary
- Revenue (Q3 2026 vs. Q3 2025): US$13,069m vs. US$12,222m (top line higher year on year)
- Net Income from Ongoing Operations (Q3 2026 vs. Q3 2025): US$2,162m vs. US$2,201m (broadly stable profit year on year)
- Basic EPS (Q3 2026 vs. Q3 2025): US$1.06 vs. US$1.08 (per share earnings slightly softer year on year)
- Gross Margin (Q3 2026): 68.4% (reflects Bristol-Myers Squibb’s high value drug portfolio economics)
Bristol Myers Squibb raised guidance after multiple late‑stage wins. Ask Charlie what derisked Bristol Myers Squibb's pipeline this quarter.
Bristol-Myers Squibb’s Growth Mix Meets Bullish Test
Optimistic analysts argue Bristol-Myers Squibb can steadily swap out legacy cash cows for newer oncology and cardiovascular drugs. That ambition is summed up here.
"Bullish analysts expect Bristol-Myers Squibb to keep shifting revenue toward its newer oncology, cardiovascular, and immunology drugs as growth products such as Eliquis, Reblozyl, Breyanzi, Opdualag, Camzyos, Qvantig and Sotyktu scale from their current contribution of nearly 60% of total sales."
Q3 results show that thesis clearing real hurdles. Growth portfolio revenue reached US$7.7b and rose 12% year on year, while the legacy basket moved only 1%. Double digit expansion in products like Qvantig, Reblozyl and Camzyos indicates that the revenue mix is tilting toward the newer portfolio as described.
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all.
Bear Case On Patent Gap Still Waiting For Proof
Bearish research argues Bristol-Myers Squibb will not bridge the post patent earnings hole.
"While Bristol-Myers Squibb is repositioning its cardiovascular franchise around milvexian, the delay of the pivotal atrial fibrillation trial into Q1 2027 extends the period of uncertainty around Eliquis replacement and raises the risk that revenue and earnings feel a gap as the 2028 patent expiry approaches."
Q3 results partly push that concern out in time. Eliquis still carries legacy revenue higher and growth drugs delivered 12% expansion. Yet there is no readout that advances milvexian, and guidance still leans on Eliquis through 2027. The gap is not closed; it is just masked for now.
Hunt Quiet Dislocations Before They Fade
Bristol-Myers Squibb just showed how a solid revenue mix can sit beside visible earnings pressure. The real opportunity could sit in stocks that look mispriced before sentiment catches up.
- Company 1 - 37% below our estimate - uses recent bank acquisitions, cheaper funding and digital upgrades to reshape a more efficient, diversified lending and deposit franchise.
- Company 2 - 20% below our estimate - grows a money platform as more customers hold balances, earn shared interest and access partner banks through embedded payment infrastructure.
- Company 3 - 30% below our estimate - ties cloud infrastructure, workplace software and developer tools together so enterprises can move everyday workflows and AI projects into one ecosystem.
That is three of the list. See all 30 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com